SecBot SecBot
8-K ·Filed Sep 11, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 9/10
Horizondays Processed2mo ago SEC0001193125-26-388621
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

This is a high-probability distress event with a very short timeline. The October 15, 2026 forbearance deadline creates a binary catalyst: either the company secures a rescue financing, strategic transaction, or extension, or it faces acceleration of all debt and likely bankruptcy. The $20M preferred stock issuance at a $1.62 conversion price (vs. current market) signals deep distress and will dilute common equity if converted. Monitor for any pre-market announcements regarding FDA acceptance of the sNDA for selinexor in myelofibrosis, which is a termination trigger if rejected, or any news of a capital raise or strategic alternative.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$1.61
T+0 close · Sep 11, 2026 · via day close
Latest settled
−62.42%
T+20 · $0.6050 · next T+60 in 20d
Vs SPY
−64.29%
α at T+20
Latest observation
−54.92%
T+22 · FF3 residual α
  1. T+0 · Sep 11 $1.61entry
  2. T+1 · 2mo ago −0.62%α −0.17% · $1.60
  3. T+5 · 2mo ago +16.77%α +16.99% · $1.88
  4. T+20 · 6w ago −62.42%α −64.29% · $0.6050
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm Therapeutics has entered into a forbearance agreement with 100% of its term loan lenders, convertible noteholders, and royalty investors, after failing to make a ~$15.8M principal payment due September 10, 2026, and not expecting to pay cash interest due September 30, 2026. The forbearance period runs to October 15, 2026, providing a short window to negotiate a restructuring, raise equity, or pursue strategic alternatives, but the company explicitly states that absent additional funding, it will be unable to continue as a going concern and may seek bankruptcy protection. As consideration, the company will issue $20M of convertible preferred stock (convertible at $1.62/share) to the consenting lenders, adding further dilution risk to common equity holders.

Key Financial Metrics

Offering Size
$20.0M

Key Facts

  • Company did not pay ~$15.8M principal installment due September 10, 2026 under its Term Loan Credit Agreement.
  • Company does not expect to pay cash interest due September 30, 2026 under the Credit Agreement and Indentures.
  • Company did not make cash interest payments on the 2028 and 2029 Notes on June 30, 2026 (~$2.8M in unpaid interest).
  • Forbearance period runs only until October 15, 2026, providing a very short runway.
  • Company states that absent additional funding, it will be unable to continue as a going concern and may seek bankruptcy protection.
  • Company will issue $20M of 0% convertible perpetual preferred stock (20,000 shares at $1,000/share, convertible at $1.62/share) as forbearance consideration to lenders.
  • As of September 10, 2026, ~$129.0M of term loan principal, $15.6M of 2028 Notes, and $108.0M of 2029 Notes were outstanding.
  • Future royalty obligations under the Royalty Agreement totaled $113.5M as of September 10, 2026.
  • Company expects existing liquidity to fund operations only until October 15, 2026.
  • Liquidity covenant under debt agreements requires $25M minimum after October 10, 2026, which the company may not satisfy.

Financial Impact

Company has ~$252.6M in total debt (term loan $129.0M, 2028 Notes $15.6M, 2029 Notes $108.0M) plus $113.5M in future royalty obligations. $20M in convertible preferred stock issued as forbearance fee. Cash runway only through October 15, 2026.

debtliquiditydilutiongoing concern

Risk Factors

  • Forbearance period expires October 15, 2026, very limited time to restructure or raise capital.
  • Any adverse FDA action on the sNDA for selinexor/myelofibrosis triggers immediate termination of forbearance.
  • Consolidated liquidity falling below $10M triggers immediate termination of forbearance.
  • If forbearance terminates, all overdue amounts become immediately due and payable in cash, likely forcing bankruptcy.
  • $20M convertible preferred stock issuance at $1.62/share conversion price creates significant dilution risk for common shareholders.
  • Company explicitly states it may be unable to continue as a going concern absent additional funding.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-388621
Document: d94769dex102.htm0001193125-26-388621
Document: d94769d8k.htm0001193125-26-388621
Document: 0001193125-26-388621-index-headers.html0001193125-26-388621
Document: 0001193125-26-388621-index.html0001193125-26-388621
Document: 0001193125-26-388621.txt0001193125-26-388621

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026